scholarly article | Q13442814 |
P50 | author | Jorge Eduardo Cortes | Q60320900 |
Hagop Kantarjian | Q60394812 | ||
Srdan Verstovsek | Q64026418 | ||
Josef T Prchal | Q88569926 | ||
Carlos B Bueso-Ramos | Q90223571 | ||
Roberto H Nussenzveig | Q90764300 | ||
Taghi Manshouri | Q91467065 | ||
Matjaž Sever | Q114304868 | ||
Pat Ault | Q114428008 | ||
P2093 | author name string | Alfonso Quintás-Cardama | |
P2860 | cites work | A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera | Q28241887 |
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells | Q28277030 | ||
JAK2 is associated with the c-kit proto-oncogene product and is phosphorylated in response to stem cell factor | Q28637652 | ||
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis | Q29614337 | ||
A gain-of-function mutation of JAK2 in myeloproliferative disorders | Q29618851 | ||
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders | Q29618853 | ||
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome | Q33336718 | ||
JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. | Q33371084 | ||
Molecular basis for polycythemia | Q33544141 | ||
Identification of an acquired JAK2 mutation in polycythemia vera | Q33947635 | ||
Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders | Q35771147 | ||
Treatment of polycythemia vera with recombinant interferon alpha (rIFNalpha) or imatinib mesylate | Q36113013 | ||
Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia | Q37405046 | ||
Imatinib effect on growth and signal transduction in polycythemia vera | Q40127047 | ||
Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. | Q43031345 | ||
Polycythemia vera responds to imatinib mesylate | Q44364237 | ||
Imatinib mesylate inhibits autonomous erythropoiesis in patients with polycythemia vera in vitro | Q44451881 | ||
Imatinib mesylate (Gleevec(TM)) reduces phlebotomy requirements in polycythemia vera | Q44452184 | ||
Imatinib mesylate in polycythemia vera | Q44834834 | ||
Phase II open label trial of imatinib in polycythemia rubra vera | Q46246672 | ||
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders | Q46513376 | ||
Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha | Q46849974 | ||
Identification of c-Kit gene mutations in patients with polycythemia vera | Q46930055 | ||
Letter: Bone-marrow responses in polycythemia vera | Q47871256 | ||
Polycythemia vera is not initiated by JAK2V617F mutation. | Q54564679 | ||
JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less? | Q58455742 | ||
P433 | issue | 1 | |
P921 | main subject | imatinib | Q177094 |
polycythemia vera | Q948318 | ||
P304 | page(s) | 58-63 | |
P577 | publication date | 2009-05-30 | |
P1433 | published in | International Journal of Hematology | Q6051416 |
P1476 | title | Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001 | |
P478 | volume | 90 |
Q43731510 | Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study |
Q38130749 | Emerging drugs for polycythemia vera |
Q37833893 | Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond |
Q38081267 | Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance |
Q37869152 | New JAK2 inhibitors for myeloproliferative neoplasms |
Q38774457 | Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera? |
Search more.